Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer

Gene Expression Signature and Immunohistochemical Markers Associated With Response to Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer

The purpose of this study is to analyze gene expression signature and immunohistochemical markers associated with clinical and pathological response to neoadjuvant chemotherapy in locally advanced breast cancer.

Locally advanced breast cancer is a common condition in development countries. Neoadjuvant chemotherapy gives the opportunity to identify genetic signatures associated with objective clinical and pathological complete responses.

Patients will receive doxorubicin/cyclophosphamide with paclitaxel. Tumor samples collected before and after chemotherapy will be analyzed.

Inclusion Criteria:

• Women with locally advanced women breast cancer
• Histology: ductal ou lobular invasive histology
• Agreement to take part in the study and signature of the informed consent
• Clinical condition to receive doxorubicin/cyclophosphamide and paclitaxel
• ECOG 0 or I

Exclusion Criteria:

• Not clinical stage III
• Inflammatory breast cancer
• Previous treatment
• Previous diagnosis of cancer (except basal cell or squamous cell skin carcinoma and non-invasive cervical carcinoma)
• Pregnancy
• Absence of clinical condition to receive chemotherapy